Shares of Cencora (NYSE: COR) and Stevanato Group (NYSE: STVN) are down more than 17% and 5%, respectively, so far this year.
This is despite solid first-quarter earnings and steady business models
Cencora, formerly known as AmerisourceBergen, is one of the dominant forces in the global pharmaceutical supply chain. Together with McKesson and Cardinal Health, it forms an effective triopoly that distributes roughly 90% of all medicines in the United States. Italian-based Stevanato is a dominant company in the drug containment and delivery systems sector.
The healthcare conglomerate manufactures prefilled syringes, vials, cartridges, and complex autoinjectors used by major pharmaceutical companies. A few reasons to buy each stock: Cencora just upgraded its 2026 earnings guidance Cencora reported its second-quarter results on May 6, and a few weeks later, raised its full-year fiscal 2026 adjusted diluted earnings per share (EPS) guidance to a range of $17.70 to $17.90, up from the previous $17.65 to $17.90. In the second quarter, Cencora reported revenue of $78.4 billion, up 3.8% year over year, primarily thanks to a 13% increase in its International Healthcare Solutions revenue and a 2.9% rise in U.S.